CD274 and non-small cell lung carcinoma: Immune checkpoint blockers (ICB), in particular inhibitors of programmed death-(ligand)-1 (PD-(L)1), are routinely used in the treatment of advanced non-small cell lung cancers (NSCLC) and significantly improve patient prognosis [1, 2].